Rikhia Chakraborty

List of Publications by Year
in descending order

32 papers	1,363 citations	567144 15 h-index	580701 25 g-index
33 all docs	33 docs citations	33 times ranked	1800 citing authors

#	Article	IF	Citations
1	Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. Blood, 2014, 124, 3007-3015.	0.6	352
2	BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. Journal of Experimental Medicine, 2014, 211, 669-683.	4.2	346
3	Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis. Blood, 2016, 128, 2533-2537.	0.6	122
4	Differentiating Skin-Limited and Multisystem Langerhans CellÂHistiocytosis. Journal of Pediatrics, 2014, 165, 990-996.	0.9	77
5	CNS Langerhans cell histiocytosis: Common hematopoietic origin for LCHâ€associated neurodegeneration and mass lesions. Cancer, 2018, 124, 2607-2620.	2.0	73
6	RAF/MEK/extracellular signalâ€“related kinase pathway suppresses dendritic cell migration and traps dendritic cells in Langerhans cell histiocytosis lesions. Journal of Experimental Medicine, 2018, 215, 319-336.	4.2	58
7	BRAFV600E-induced senescence drives Langerhans cell histiocytosis pathophysiology. Nature Medicine, 2021, 27, 851-861.	15.2	38
8	New somatic BRAF splicing mutation in Langerhans cell histiocytosis. Molecular Cancer, 2017, 16, 115.	7.9	37
9	Robust and cost effective expansion of human regulatory T cells highly functional in a xenograft model of graft-versus-host disease. Haematologica, 2013, 98, 533-537.	1.7	30
10	Circulating CD1c+ myeloid dendritic cells are potential precursors to LCH lesion CD1a+CD207+ cells. Blood Advances, 2020, 4, 87-99.	2.5	25
11	Overcoming T-cell exhaustion in LCH: PD-1 blockade and targeted MAPK inhibition are synergistic in a mouse model of LCH. Blood, 2021, 137, 1777-1791.	0.6	25
12	Activating MAPK1 (ERK2) mutation in an aggressive case of disseminated juvenile xanthogranuloma. Oncotarget, 2017, 8, 46065-46070.	0.8	24
13	p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy. Clinical Cancer Research, 2017, 23, 6629-6639.	3.2	23
14	IFN-Î³ signature in the plasma proteome distinguishes pediatric hemophagocytic lymphohistiocytosis from sepsis and SIRS. Blood Advances, 2021, 5, 3457-3467.	2.5	23
15	MAP-Kinase-Driven Hematopoietic Neoplasms: A Decade of Progress in the Molecular Age. Cold Spring Harbor Perspectives in Medicine, 2021, 11, a034892.	2.9	17
16	A genome-wide association study of LCH identifies a variant in SMAD6 associated with susceptibility. Blood, 2017, 130, 2229-2232.	0.6	15
17	Changes in Chemokine Receptor Expression of Regulatory T Cells After Ex Vivo Culture. Journal of Immunotherapy, 2012, 35, 329-336.	1.2	9
18	Evaluation of maternal and perinatal characteristics on childhood lymphoma risk: A populationâ€based caseâ€control study. Pediatric Blood and Cancer, 2017, 64, e26321.	0.8	7

#	Article	IF	Citations
19	BRAFV 600E or mutant MAP2K1 human CD34+ cells establish Langerhans cellâ€“like histiocytosis in immune-deficient mice. Blood Advances, 2020, 4, 4912-4917.	2.5	6
20	Defining the Inflammatory Plasma Proteome in Pediatric Hodgkin Lymphoma. Cancers, 2020, 12, 3603.	1.7	6
21	Cellular distribution of mutations and association with disease risk inÂLangerhans cell histiocytosis without BRAFV600E. Blood Advances, 2022, 6, 4901-4904.	2.5	4
22	Mutually Exclusive Recurrent Somatic Mutations in MAP2K1 and BRAF Support a Central Role for ERK Activation in LCH Pathogenesis. Blood, 2014, 124, 5587-5587.	0.6	2
23	The "Gatekeeper" Mutation T315I in BCR/ABL Confers Additional Oncogenic Activities to Philadelphia Chromosome Positive Leukemia. Blood, 2019, 134, 5196-5196.	0.6	2
24	BRAFV600E vs cell of origin: what governs LCH?. Blood, 2021, 138, 1203-1204.	0.6	1
25	Plasma Biomarker Profiling In Langerhans Cell Histiocytosis: Risk-Stratifying The Inflammatory Storm. Blood, 2013, 122, 2854-2854.	0.6	0
26	Inflammatory Plasma Proteins Predict Disease Severity and Response to Therapy in Patients with LCH. Blood, 2015, 126, 4072-4072.	0.6	0
27	A Genome-Wide Assessment of Inherited Genetic Variants and the Risk of Langerhans Cell Histiocytosis. Blood, 2015, 126, 4059-4059.	0.6	0
28	Inherited Genetic Risk Factors and Langerhans Cell Histiocytosis Relapse Events. Blood, 2018, 132, 4278-4278.	0.6	0
29	Whole Exome Analysis Reveals Key Genomic Differences between Sporadic and Endemic Pediatric Burkitt Lymphoma. Blood, 2018, 132, 4117-4117.	0.6	0
30	Blocking MAPK Activation and Immune Checkpoints Reverse Immune Dysfunction and Reduce Disease in a Mouse Model of LCH. Blood, 2019, 134, 3602-3602.	0.6	0
31	TCR Repertoire Clonality Analysis and Transcriptome Analyses of Immune Infiltrates in Patients with Langerhans Cell Histiocytosis Can Define Prognostic Biomarkers for Future Therapeutic Development. Blood, 2019, 134, 3601-3601.	0.6	0
32	Comprehensive Cell Specific Transcriptome Profiling of a Pediatric Hodgkin Lymphoma Cohort. Blood, 2019, 134, 2773-2773.	0.6	0